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CASE REPORT
Considerable Variability in the Efficacy of 8% Capsaicin 
Topical Patches in the Treatment of Chronic Pruritus in 
3 Patients with Notalgia Paresthetica
Hjalte H. Andersen, Carsten Sand1, Jesper Elberling2
Center of Sensory-Motor Interaction, Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Aalborg, 
1Dermato-venerological Department, Bispebjerg Hospital, Copenhagen, 2The Allergy Clinic, Copenhagen University Hospital Gentofte, 
Gentofte, Denmark
Notalgia paresthetica (NP) is a focal neuropathic itch con-
dition manifesting in intense chronic or recurrent episodic 
itch in a hyperpigmented, macular, uni- or bilateral skin area 
located below and/or medially to the scapulae. Achieving 
satisfactory relieve in NP patients is challenging. In this 
case-series three female NP patients were treated with 8% 
capsaicin patches following a spatial quantification of their 
alloknetic area with a von Frey filament. The use of a von Frey 
filament in order to delimit the precise area of itch sensitiza-
tion and thus patch application, proved clinically feasible. 
Although 8% topical capsaicin relieved itch in all three pa-
tients, the duration of the effectiveness varied greatly from 
only 3 days to ＞2 months. The treatment was well tolerated 
in the patients and there appear to be no significant hin-
drances to applying this treatment with NP as an indication, 
although it may only exhibit satisfactory effectiveness in cer-
tain patients. Placebo-controlled double-blinded trials are 
needed to confirm the effectiveness of the treatment and as-
sess predictive parameters of the treatment outcome. (Ann 
Dermatol 28(1) 86∼89, 2016)
-Keywords-
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INTRODUCTION
Notalgia paresthetica (NP) is a focal neuropathic itch con-
dition that presents as a macular, unilateral or bilateral 
skin area located below and/or medially to the scapulae, 
giving rise to intense chronic itch frequently accompanied 
by post-inflammatory hyperpigmentation1,2. Although the 
chronic pruritus (CP) of NP is known to significantly im-
pede life quality, the condition is estimated to be under-
diagnosed and no evidence-based treatment regimen is 
currently established3. 
Casuistically, transient relief of itch in NP has been re-
ported upon treatment with anticonvulsants, transcutaneous 
nervous stimulation, and botulinum toxin-A3-7. However, 
the effect of the latter was recently shown to be irreprodu-
cible in a small double-blinded study of 20 patients with 
NP8. In addition, high-concentration topical capsaicin 
treatment has occasionally been shown to alleviate itch in 
NP, most notably in two cases in which a considerable ef-
ficacy of 8% capsaicin topical patches was observed9. 
Capsaicin causes intense depolarization of epidermal tran-
sient receptor potential vanilloid 1 (TRPV1)-positive pru-
ritic and nociceptive C-fibers10, resulting in prolonged, re-
versible deafferentation and defunctionalization. Qutenza 
(Astellas Pharma, Kastrup, Denmark) offers topical patch 
delivery of 8% capsaicin and is approved for the treatment 
of painful post-herpetic neuralgia11. 
CP is often associated with itch-related dysesthesias, such 
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Fig. 1. Cases 1∼3 before (A), 
during (B), and after (C) application 
of capsaicin. The blue marker 
signifies the predetermined area of 
alloknesis to von Frey pinprick. 
Notice that the area of alloknesis 
is larger than that of hyperpig-
mentation, particularly in case 1 
and 3 and to a lesser extent in case 
2. As evident in all 3 cases (B and 
C), the erythema extends beyond the 
area of application highlighting cap-
saicin-induced activation of C-me-
chano-insensitive-fibers.
as alloknesis, i.e. the perception of itch in response to nor-
mally innocuous stimuli, which is a concern for patient 
well-being and has not yet been assessed in patients with 
NP12. Here, the feasibility of using a 10 g Semmes-Weins-
tein nylon monofilament for sensory testing to map the 
area of alloknesis (similarly to the approach outlined in13) 
as a psychophysical biomarker and specifically treating 
this area was assessed. The present case series describes 
three severe NP cases in which treatment with 8% cap-
saicin provided a clinically significant decrease in itch in-




A 54-year-old menopausal woman was referred due to 
long-standing intense itch, anatomically coinciding with 
hyperpigmentation of the upper right back (Fig. 1, 1A). 
The patient reported constant itch, rated 8∼10 on a visual 
analog scale (visual analogue scale [VAS], 0∼10; 0 denot-
ing “no itch” and 10 denoting “worst imaginable itch”) 
and severe, consistent sleep difficulties due to frequent 
nocturnal bouts of itching.
Previous unsuccessful attempts to treat her NP-induced CP 
included topical treatment with antifungal, corticosteroid, 
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Fig. 2. Case 1 at follow-up (and 2nd treatment), 3 months 
following the initial treatment. Notice the significantly retracted 
area of alloknesis indicated by the black demarcation (Fig. 1A, 
B for comparison). The patient also exhibited diminished 
hyperpigmentation.
tacrolimus 0.1%, capsaicin 0.025%, and doxepin 5% 
creams. Only topical doxepin was shown to provide some 
relief (2∼3 hours duration), but did not effectively relieve 
nightly bouts of itch. Histological examination of a 3-mm 
punch biopsy confirmed the presence of postinflammatory 
hyperpigmentation. The area of alloknesis was identified, 
which corresponded with the area of hyperpigmentation, 
except for a 2∼4 cm border area with little or no hyper-
pigmentation.
After informed consent was obtained, the patient was 
treated with a topical 8% capsaicin patch for 1 hour. The 
treatment resulted in 7 weeks of complete itch relief, upon 
which a slow but steady reversal began. During re-exami-
nation and retreatment 3 months after the initial treatment, 
the patient reported that the returned CP was once again 
highly bothersome and sleep disruptive, but not entirely to 
the same extent as before the initial treatment. Of note, 
the intensity but not the area of the hyperpigmentation 
and the area of alloknesis to the nylon filament stimuli had 
diminished after the first treatment. Subsequent treatments 
with capsaicin 8% had comparable efficacy. By the third 
treatment, the area of alloknesis had retracted by approx-
imately 15%∼25% (Fig. 2).
Case 2
A 49-year-old woman presented with itching and sym-
metrical bilateral hyperpigmentation below and medially 
to the scapulae (Fig. 1, 1B). She stated that the condition 
had emerged 5∼6 years previously and reported 4∼6 
daily itch exacerbations, the itch intensity of which she 
rated at VAS=9. The patient also expressed concerns re-
garding the implications of the discoloration on her aes-
thetic appearance. The patient had undergone topical and 
systemic antifungal therapies in previous unsuccessful at-
tempts to treat her pruritus. A biopsy revealed postin-
flammatory hyperpigmentation. The area of alloknesis 
slightly exceeded the area of hyperpigmentation.
After obtaining informed consent, the patient was treated 
with a topical 8% capsaicin patch for 1 hour. At fol-
low-up, the patient reported that her itch had disappeared 
completely for 1 week, and thereafter very slowly receded 
toward baseline levels. Despite this slow reversal, the pa-
tient reported that, at the 3-month follow-up/retreatment, 
her average itch intensity remained lower compared to 
her pretreatment baseline levels of itch. At retreatment af-
ter 3 months, both the hyperpigmentation and the area of 
alloknesis had decreased considerably.
Case 3
A 45-year-old woman was referred due to moderate itch 
of the upper back estimated to have persisted for approx-
imately 20 years. The patient reported a constant itch rat-
ed at 3 on a VAS (0∼10) and 1∼3 daily itch exacer-
bations, the intensity of which she rated as 6∼9. She re-
ported experiencing typically two nightly itch-and-scratch 
bouts lasting several minutes each. She was taking no con-
comitant medication.
Inspection revealed no visible skin alterations in the area 
where the itch was perceived — medially to the left scap-
ula (Fig. 1, 1C). The area of alloknesis could be identified 
using a 10 g nylon filament. After informed consent was 
obtained, the patient was treated with a topical 8% cap-
saicin patch for 1 hour. At follow-up, the patient reported 
that the itch had subsided completely for 2 days but there-
after rapidly returned to baseline levels. She underwent 
one additional treatment 3 months after with a similarly 
subpar treatment outcome.
DISCUSSION
Achieving satisfactory relief in patients suffering from neu-
ropathic itch such as in NP is highly challenging. Etiologi-
cally, the involvement of the spinal nerves T2∼T6 in NP 
is quite evident, but the nature of the pathophysiology at 
play in NP is unclear1. First, a reduced density of intra-epi-
dermal sensory nerve fibers has been observed in NP-af-
fected skin, which is paradoxically also a well-established 
reversible effect of high-concentration capsaicin1. Second, 
older literature hypothesized musculoskeletal impinge-
ment of the thoracic nerves, but supporting evidence is 
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sparse1,14. Because the primary mechanism of action of 
topical capsaicin is a defunctionalization of intra-epi-
dermal fibers, the apparent effectiveness of capsaicin in 
NP patients indicates a pathophysiological contribution 
from peripheral TRPV1+ C-fibers.
In the present case series, all subjects had significant er-
ythema and moderate pain at the patch site during the ap-
plication and ≈15∼60 minutes after patch removal. No 
other side effects were reported, and the treatment-indu-
ced erythema did not evoke secondary hyperpigmentation 
in any of the subjects. The underlying cause of this notice-
able difference in treatment response in NP is unknown, 
but similar response variation has been observed in the 
treatment of post-herpetic neuralgia15. Of interest, as can 
be seen in Fig. 1, 1A and 1B, the area of alloknesis ex-
tended beyond the hyperpigmented area, hinting that CP 
in NP might present as an area of spontaneously occurring 
itch with an area of alloknesis within its perimeter, where-
in touch-evoked but not spontaneous itching occurs, thus 
making it less prone to frequent scratching and hence, to 
inflammation-induced hyperpigmentation.
Because the sensation of itch has low spatial resolution, 
identifying the location and exact area of itch is not a trivi-
al task, particularly in patients without hyperpigmentation. 
It is concluded that it is clinically feasible to delimit the 
area of alloknesis, i.e., the itch-hypersensitive area with a 
10 g von Frey filament (Fodplejedepotet HEWA, Gentofte, 
Denmark) in patients with NP. Two noticeable ob-
servations were made in the NP-affected skin in response 
to treatment. The area of hyperpigmentation diminished in 
size and/or intensity, and accordingly, the area of allokne-
sis was significantly reduced. This indicates that these pa-
rameters, when present, could be of potential use as se-
verity/treatment response biomarkers if implemented in 
the routine assessment of NP.
The three patients reported here all experienced immedi-
ate relief of itch in response to 8% topical capsaicin, but 
the duration of the alleviation varied considerably. Studies 
exploring the potential prediction of treatment outcome to 
high-concentration capsaicin are warranted, particularly in 
light of the current price of the treatment. Qutenza 
(Astellas Pharma) was well tolerated by the patients, and 
there appear to be no significant hindrances to applying 
this treatment with NP as an indication.
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